{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:02:40Z","timestamp":1790874160374,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clml.2026.07.004","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:41:58Z","timestamp":1783957318000},"page":"698-705.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safe Integration of Radiation Therapy With Bispecific Antibodies in Relapsed\/Refractory B-cell Lymphomas"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3835-5750","authenticated-orcid":false,"given":"Jonathan A.","family":"Baron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Chelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurbani","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0145-8684","authenticated-orcid":false,"given":"Michael D.","family":"Schad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8679-6391","authenticated-orcid":false,"given":"Melanie","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline R.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan S.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita D.","family":"Nasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Landsburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-5271","authenticated-orcid":false,"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Yegya-Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"LaRiviere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Plastaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise A.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4812-5235","authenticated-orcid":false,"given":"Harper","family":"Hubbeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.07.004_bib0001","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.004_bib0002","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.07.004_bib0003","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.004_bib0004","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.07.004_bib0005","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-Cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.07.004_bib0006","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (bite) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.004_bib0007","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/bloodadvances.2024013640","article-title":"Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas","volume":"9","author":"Chong","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.004_bib0008","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/j.prro.2020.11.003","article-title":"Efficacy of palliative radiation therapy (RT) for chemotherapy relapsed or refractory diffuse large B-cell lymphoma: a population-based retrospective review","volume":"11","author":"Wong","year":"2021","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.07.004_bib0009","doi-asserted-by":"crossref","first-page":"101016","DOI":"10.1016\/j.adro.2022.101016","article-title":"Radiation therapy for relapsed or refractory diffuse large B-cell lymphoma: what is the right regimen for palliation?","volume":"7","author":"Wright","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.clml.2026.07.004_bib0010","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.clml.2021.05.007","article-title":"Palliative radiotherapy for diffuse large B-cell lymphoma","volume":"21","author":"Wright","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.07.004_bib0011","first-page":"1","article-title":"Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2026.07.004_bib0012","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/bloodadvances.2025015855","article-title":"Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study","volume":"9","author":"Yegya-Raman","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.004_bib0013","doi-asserted-by":"crossref","first-page":"1517348","DOI":"10.3389\/fimmu.2025.1517348","article-title":"Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas","volume":"16","author":"Manzar","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2026.07.004_bib0014","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging radiation therapy before commercial chimeric antigen receptor T-cell therapy for relapsed or refractory aggressive B-cell lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2026.07.004_bib0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.radonc.2022.10.018","article-title":"Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed\/refractory aggressive B-cell lymphoma","volume":"177","author":"Yu","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clml.2026.07.004_bib0016","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2026.07.004_bib0017","doi-asserted-by":"crossref","first-page":"114075","DOI":"10.1016\/j.ejca.2024.114075","article-title":"Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review","volume":"205","author":"G\u00e9raud","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2026.07.004_bib0018","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.07.004_bib0019","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2026.07.004_bib0020","doi-asserted-by":"crossref","first-page":"111386","DOI":"10.1016\/j.radonc.2026.111386","article-title":"Outcomes of combined bispecific antibody and radiation therapy in relapsed\/refractory hematologic malignancies","volume":"217","author":"Ababneh","year":"2026","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clml.2026.07.004_bib0021","article-title":"Radiation-induced lymphopenia: a data compilation to unveil relevant factors and mitigation strategies","volume":"56","author":"Sandul","year":"2026","journal-title":"Clin Transl Rad Oncol"},{"key":"10.1016\/j.clml.2026.07.004_bib0022","article-title":"Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed\/refractory multiple myeloma","author":"Patel","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.004_bib0023","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:16:31Z","timestamp":1790871391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026002090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2152265026002090"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safe Integration of Radiation Therapy With Bispecific Antibodies in Relapsed\/Refractory B-cell Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}